Compare Ascendis Pharma A/S (ASND) vs The Coca-Cola Co K (KO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs The Coca-Cola Co K — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while The Coca-Cola Co K trades at $83.75 (market cap $359.21B). The key difference: The Coca-Cola Co K is far larger — about 20.2× Ascendis Pharma A/S's market cap, and The Coca-Cola Co K pays a 2.54% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KO | |
|---|---|---|
Market Cap | $17.74B | $359.21B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $84.14 |
52-Week Low | $163.32 | $65.67 |
Enterprise Value | $18.11B | $389.28B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Coca-Cola (KO) trades at $83.49, up 1.04% today, with a bullish technical signal from moving averages and strong analyst support. The company reported consistent earnings beats in recent quarters and maintains robust profitability with a 27.8% net income margin. Recent news highlights institutional buying and stable demand trends, though regional divergences exist.
The outlook is positive with a consensus price target of $89, offering ~6.6% upside. Key risks include high valuation multiples and macroeconomic sensitivity. The stock remains a core holding for dividend growth, supported by 64 consecutive years of dividend increases and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
